A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Conditions

• Major Depressive Disorder (MDD)

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• DT-101 — DRUG
  DT-101 A
• DT-101 — DRUG
  DT-101 B
• Placebo — DRUG
  Placebo

Study Details

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

Key Dates

Start date

Dec 16, 2025

Status verified

Dec 2025

Primary completion

Aug 31, 2027

Completion

Aug 31, 2027

Study Design

Enrollment

300 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: DT-101 A
• Experimental: DT-101 B
• Placebo Comparator: Placebo

Primary Outcome Measure

Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 42 [ Time Frame: from enrollment to day 42 ]

Central Contacts

• Chief Medical Officer
  +44(0)2920028450
  [email protected]

Locations (23)

Find similar trials in Bentonville, AR

Related Studies

• Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
  EARLY_PHASE1 · Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
• A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
  PHASE3 · Recruiting · Cybin IRL Limited · Birmingham, Alabama
• Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
  PHASE3 · Recruiting · Vanda Pharmaceuticals · Phoenix, Arizona
• Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
  PHASE2 · Recruiting · Marianne Goodman · The Bronx, New York